Collaborative Research and Development Agreements - Schedule of Milestone Achieved (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Sep. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Jun. 30, 2015
Deferred Revenue Arrangement [Line Items]
Collaboration revenue	$ 970			$ 11,247
GSK
Deferred Revenue Arrangement [Line Items]
Collaboration revenue	$ 1,000			11,200
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)
Deferred Revenue Arrangement [Line Items]
Collaboration revenue															$ 1,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | IND clearance from the FDA
Deferred Revenue Arrangement [Line Items]
Collaboration revenue													$ 4,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | Phase 2 clinical trial initiation
Deferred Revenue Arrangement [Line Items]
Collaboration revenue										$ 3,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | Phase 3 clinical trial initiation - first indication
Deferred Revenue Arrangement [Line Items]
Collaboration revenue								$ 5,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | Phase 3 clinical trial initiation - second indication
Deferred Revenue Arrangement [Line Items]
Collaboration revenue							$ 5,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | Filing of the first BLA - first indication
Deferred Revenue Arrangement [Line Items]
Collaboration revenue					$ 10,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | Filing of the first MAA - first indication
Deferred Revenue Arrangement [Line Items]
Collaboration revenue					$ 5,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | Filing of the first BLA - second indication
Deferred Revenue Arrangement [Line Items]
Collaboration revenue				$ 10,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | First BLA approval - first indication
Deferred Revenue Arrangement [Line Items]
Collaboration revenue			$ 20,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | First MAA approval - first indication
Deferred Revenue Arrangement [Line Items]
Collaboration revenue			$ 10,000
GSK | Anti-PD-1 (JEMPERLI/Dostarlimab) | First BLA approval - second indication
Deferred Revenue Arrangement [Line Items]
Collaboration revenue		$ 20,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)
Deferred Revenue Arrangement [Line Items]
Collaboration revenue														$ 1,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | IND clearance from the FDA
Deferred Revenue Arrangement [Line Items]
Collaboration revenue												$ 4,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Phase 2 clinical trial initiation
Deferred Revenue Arrangement [Line Items]
Collaboration revenue									$ 3,000
GSK | Anti-LAG-3 (GSK40974386) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)
Deferred Revenue Arrangement [Line Items]
Collaboration revenue											$ 1,000
GSK | Anti-LAG-3 (GSK40974386) | IND clearance from the FDA
Deferred Revenue Arrangement [Line Items]
Collaboration revenue										$ 4,000
GSK | Anti-LAG-3 (GSK40974386) | Phase 2 clinical trial initiation
Deferred Revenue Arrangement [Line Items]
Collaboration revenue						$ 3,000